Management of Early-Stage Non-Small Cell Lung Cancer

Initial Evaluation and Staging

Detailed locoregional staging according to the TNM staging system should be performed to determine the appropriate treatment approach for patients with non-small cell lung cancer 1
For patients with no evidence of nodal metastasis on CT and PET images, surgical resection is recommended without additional invasive staging, as suggested by the European Society for Medical Oncology 1, 2
If there is suspicion of mediastinal lymph node involvement on imaging, pathological confirmation via needle aspiration under EBUS/EUS guidance or mediastinoscopy is necessary, according to the European Society for Medical Oncology 1
Assessment of cardiopulmonary fitness is essential before surgical intervention, including formal lung function testing, as recommended by the European Society for Medical Oncology 1

For early-stage non-small cell lung cancer, anatomical resection (lobectomy) is preferred over sublobar resection as it offers better oncological outcomes, according to the American College of Chest Physicians 3, 4, 5
A minimally invasive approach such as video-assisted thoracic surgery (VATS) is preferred over thoracotomy when performed by experienced surgeons, as suggested by the American College of Chest Physicians 4, 5
Systematic mediastinal lymph node sampling or dissection should be performed during resection for accurate pathologic staging, according to the American College of Chest Physicians 3, 4, 5

If pathologic staging confirms stage I disease (no lymph node involvement), adjuvant chemotherapy is not recommended, as suggested by the American College of Chest Physicians 3, 4, 5
If pathologic staging reveals stage II disease (N1 lymph node involvement), adjuvant platinum-based chemotherapy is recommended, according to the American College of Chest Physicians 3, 4, 5
The most frequently studied regimen is cisplatin-vinorelbine, with a cumulative cisplatin dose of up to 300 mg/m² delivered in 3-4 cycles, as recommended by the European Society for Medical Oncology 1

For patients who cannot tolerate surgical resection, stereotactic ablative radiotherapy (SABR) is the non-surgical treatment of choice for stage I non-small cell lung cancer, according to the European Society for Medical Oncology and the American College of Chest Physicians 1, 3, 4
The dose should be to a biologically equivalent tumor dose of ≥100 Gy, as recommended by the European Society for Medical Oncology 1

After treatment, regular surveillance should include history, physical examination, and imaging studies, as suggested by the National Comprehensive Cancer Network 7
CT scans are typically performed every 3-6 months for the first 2 years, then annually, according to the National Comprehensive Cancer Network 7